Phase II VIRO-15 trial of olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC) (NCT02759588)

Saved in:
Bibliographic Details
Published inGynecologic oncology Vol. 159; p. 60
Main Authors Holloway, R.W., Mendivil, A.A., Kendrick, J.E., Abaid, L.N., Brown, J.V., Fitzsimmons, C.K., Kennard, J.A., King, M.M., LeBlanc, J., Lopez, K., Manyam, M., McKenzie, N.D., Mori, K.M., Smith, J.L., Stephens, A.J., Ahmad, S.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.10.2020
Online AccessGet full text

Cover

More Information
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2020.06.126